Sun Gets CGT Nod For AmBisome Rival
Awarded 180 Days Exclusivity For Amphotericin B Liposome Injection
Executive Summary
Sun Pharma is looking to target a market worth $136m after receiving US FDA approval for amphotericin B liposome with a Competitive Generic Therapy designation, bringing the promise of 180 days of CGT exclusivity for the product.
You may also be interested in...
Lupin Gives Direction On Pegfilgrastim And Ranibizumab
Indian major Lupin is continuing to further efforts on its three main growth drivers: biosimilars, inhalation products and long-acting injectables, management told the virtual J.P. Morgan Healthcare Conference in San Francisco.
Perrigo’s Loss Is Lupin’s Gain On Albuterol
Having gained from Perrigo’s US withdrawal of generic ProAir (albuterol sulphate), Lupin plans to ramp up capacity by its financial fourth quarter as demand is seen rising on account of flu and COVID-19 cases in the US. Meanwhile, FDA observations at its Somerset facility provide a dampener.
FDA Issues A Raft Of Product-Specific Guidances
The FDA has issued 36 draft product-specific guidances for generic drug development, comprising 19 new guidances and 17 revised documents.